Claims

1. Use of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of cancer in combination with a platinum-based anticancer agent selected from carboplatin, dicycloplatin, oxaliplatin, satraplatin and nedaplatin.

2. The use of claim 1, wherein the platinum-based anticancer agent is carboplatin.

3. The use of claim 1 or claim 2, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is gemcitabine-[phenyl-benzoxy-L-alaninyl)]-(S)-phosphate in substantially diastereomerically pure form.

4. The use of claim 1 or claim 2, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is a mixture of phosphate diastereoisomers.

5. The use of any one of claims 1 to 4, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is in the form of the free base.

6. The use of any one of claims 1 to 5, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is to be administered intravenously.

7. The use of any one of claims 1 to 6, wherein the cancer is selected from lung cancer, bladder cancer, breast cancer and ovarian cancer.

8. The use of claim 7, wherein the cancer is ovarian cancer.

9. The use of any one of claims 1 to 8, wherein the cancer is relapsed.

10. The use of any one of claims 1 to 9, wherein the cancer is refractory, resistant or partially resistant to the platinum-based anticancer agent.

11. The use of any one of claims 1 to 9, wherein the cancer is sensitive to the platinum-based anticancer agent.

12. The use of any one of claims 1 to 11, wherein the dose of the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate to be administered at each administration event is preferably between 250 mg/m^2 and 1250 mg/m^2 and the dose of the platinum-based anticancer agent to be administered at each administration event is selected to provide an AUC of between 2 and 5.5 $mgmL^{-1}min^{-1}$.

13. Use of a platinum-based anticancer agent selected from carboplatin, dicycloplatin, oxaliplatin, satraplatin and nedaplatin in the manufacture of a medicament for treating cancer in combination with gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, or a pharmaceutically acceptable salt or solvate thereof.

14. A pharmaceutical formulation comprising gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, or a pharmaceutically acceptable salt or solvate thereof, together with a platinum-based anticancer agent selected from carboplatin, dicycloplatin, oxaliplatin, satraplatin and nedaplatin, and at least one pharmaceutically acceptable excipient.

15. A kit comprising two separate formulations to be used together, the formulations being:

a first formulation comprising gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient; and

a second formulation comprising a platinum-based anticancer agent selected from carboplatin, dicycloplatin, oxaliplatin, satraplatin and nedaplatin and at least one pharmaceutically acceptable excipient.